Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

A DAILY pill that doubles survival time for lung cancer patients will be made routinely available on the NHS. Osimertinib, also known as Tagrisso and made by AstraZeneca, helps prevent cancer from ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung cancer, according to the agents’ manufacturer.The OS benefit with ...

UK pharma major AstraZeneca today revealed that, this week, it has received two positive recommendations from the National ...

According to Nice, osimertinib can help stop cancer from returning after surgery by targeting cells that have specific ...

Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) combination therapy for non-small cell lung ...

The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...

During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S.

Dr Reddy’s Laboratories (pemetrexed) (confidentiality agreement not signed, not participating) Eli Lilly (pemetrexed) (confidentiality agreement not signed, not participating) Genus Pharmaceuticals ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...